ArticleClinical medicine (London, England)2020
Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.
Article in Clinical medicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Communication to promote and support physical distancing for COVID-19 prevention and control: a rapid reviewThe Cochrane database of systematic reviews · 2023Pooled it
- Digital Health for Equitable Rheumatic Care: Integrating Real-World Experiences to Guide Policy Pathways.Healthcare (Basel, Switzerland) · 2025Review
- Association between SYVN1 and SEL1 genetic polymorphisms and remission in rheumatoid arthritis patients treated with TNF-α inhibitors: a machine learning approach.Immunologic research · 2023Article
- Exploring the longer-term impact of the COVID-19 pandemic on physical and mental health of people with inflammatory rheumatic diseases: a cross-sectional survey.Clinical rheumatology · 2023Article
- Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.The archives of bone and joint surgery · 2022Article
- Chronic Pain Management During a Pandemic: Evidence-Based Review.Turkish journal of anaesthesiology and reanimation · 2022Article
- Technical factors can impact on remote consultations in rheumatology: results from a service evaluation during the COVID-19 pandemic.Rheumatology international · 2022Article
- Patients' perspectives of telemedicine appointments for psoriatic arthritis during the COVID-19 pandemic: results of a patient-driven pilot survey.BMC rheumatology · 2022Article
- Perceptions of risk in people with inflammatory arthritis during the COVID-19 pandemic.Rheumatology advances in practice · 2022Article
- Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study.Archives of rheumatology · 2021Article
- Health-related quality of life, uncertainty and coping strategies in solid organ transplant recipients during shielding for the COVID-19 pandemic.Transplant international : official journal of the European Society for Organ Transplantation · 2021Article
- Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.The British journal of dermatology · 2021Article
- Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.International journal of rheumatic diseases · 2021Review
- Inflammatory arthritis in patients with COVID-19.Translational research : the journal of laboratory and clinical medicine · 2021Review
- The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection technique: prevalence and effect of social shielding.Rheumatology international · 2021Article
- Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE-data from the BSR audit of systemic lupus erythematosus.Rheumatology (Oxford, England) · 2021Article
- Systematic review of immunosuppressant guidelines in the COVID-19 pandemic.Therapeutic advances in drug safety · 2021Review
- COVID-19 and shielding: experiences of UK patients with lupus and related diseases.Rheumatology advances in practice · 2021Article
- Managing rheumatoid arthritis during COVID-19.Clinical rheumatology · 2020Review
- Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19.Clinical medicine (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.